| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALKS | Ordinary Shares | Award | +36,835 | +32% | 150,952 | 08 Feb 2024 | Direct | F1, F2 | ||
| transaction | ALKS | Ordinary Shares | Tax liability | $294,657 | -11,007 | -7.3% | $26.77 | 139,945 | 08 Feb 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $27,698 | +599 | +2% | $46.24 | 30,599 | 17 Nov 2023 | Ordinary Shares | 599 | $46.24 | Direct | F3, F4 |
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $32,750 | +469 | +2% | $69.83 | 23,969 | 17 Nov 2023 | Ordinary Shares | 469 | $69.83 | Direct | F3, F4 |
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $28,444 | +899 | +2% | $31.64 | 45,899 | 17 Nov 2023 | Ordinary Shares | 899 | $31.64 | Direct | F3, F4 |
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $37,396 | +699 | +2% | $53.50 | 35,699 | 17 Nov 2023 | Ordinary Shares | 699 | $53.50 | Direct | F3, F4 |
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $50,048 | +759 | +2% | $65.94 | 38,759 | 17 Nov 2023 | Ordinary Shares | 759 | $65.94 | Direct | F3, F4 |
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $47,544 | +1,489 | +2% | $31.93 | 75,989 | 17 Nov 2023 | Ordinary Shares | 1,489 | $31.93 | Direct | F3, F4 |
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $30,726 | +1,534 | +2% | $20.03 | 78,287 | 17 Nov 2023 | Ordinary Shares | 1,534 | $20.03 | Direct | F3, F5 |
| transaction | ALKS | Restricted Stock Unit Award | Other | +91 | +2% | 4,680 | 17 Nov 2023 | Ordinary Shares | 91 | Direct | F3, F6, F7 | |||
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $59,993 | +3,102 | +2% | $19.34 | 158,221 | 17 Nov 2023 | Ordinary Shares | 3,102 | $19.34 | Direct | F3, F8 |
| transaction | ALKS | Restricted Stock Unit Award | Other | +380 | +2% | 19,387 | 17 Nov 2023 | Ordinary Shares | 380 | Direct | F3, F6, F9 | |||
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $68,606 | +2,790 | +2% | $24.59 | 142,344 | 17 Nov 2023 | Ordinary Shares | 2,790 | $24.59 | Direct | F3, F10 |
| transaction | ALKS | Restricted Stock Unit Award | Other | +523 | +2% | 26,690 | 17 Nov 2023 | Ordinary Shares | 523 | Direct | F3, F6, F11 | |||
| transaction | ALKS | Employee Stock Option (Right to Buy) | Other | $73,514 | +2,741 | +2% | $26.82 | 139,803 | 17 Nov 2023 | Ordinary Shares | 2,741 | $26.82 | Direct | F3, F12 |
| transaction | ALKS | Restricted Stock Unit Award | Other | +685 | +2% | 34,951 | 17 Nov 2023 | Ordinary Shares | 685 | Direct | F3, F6, F13 |
| Id | Content |
|---|---|
| F1 | Late filing due to administrative error. |
| F2 | These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. |
| F3 | Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. |
| F4 | These options are fully vested in accordance with their terms. |
| F5 | Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021. |
| F6 | Each restricted stock unit represents a contingent right to receive one ordinary share. |
| F7 | Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. |
| F8 | Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. |
| F9 | Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. |
| F10 | Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. |
| F11 | Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. |
| F12 | Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. |
| F13 | Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. |
EXHIBIT LIST: Exhibit 24.1 - Power of Attorney